Biopartners goes biobetter as sustained release hGH shows Phase III promise
This article was originally published in Scrip
Biopartners, a Swiss firm focused on biogenerics, and LG Life Sciences (LGLS; South Korea) have presented positive Phase III results of 24 months efficacy and safety in children with growth hormone deficiency (GHD) for LB03002, a once-a-week, sustained release recombinant human growth hormone (hGH), at the annual meeting of the European Society for Paediatric Endocrinology (ESPE 2011) in Glasgow, Scotland.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.